1. Home
  2. CCO vs ORKA Comparison

CCO vs ORKA Comparison

Compare CCO & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CCO
  • ORKA
  • Stock Information
  • Founded
  • CCO 1995
  • ORKA 2004
  • Country
  • CCO United States
  • ORKA United States
  • Employees
  • CCO N/A
  • ORKA N/A
  • Industry
  • CCO Advertising
  • ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • CCO Consumer Discretionary
  • ORKA Health Care
  • Exchange
  • CCO Nasdaq
  • ORKA Nasdaq
  • Market Cap
  • CCO 586.5M
  • ORKA 580.3M
  • IPO Year
  • CCO 2005
  • ORKA N/A
  • Fundamental
  • Price
  • CCO $1.28
  • ORKA $15.44
  • Analyst Decision
  • CCO Hold
  • ORKA Strong Buy
  • Analyst Count
  • CCO 5
  • ORKA 9
  • Target Price
  • CCO $1.88
  • ORKA $40.38
  • AVG Volume (30 Days)
  • CCO 4.0M
  • ORKA 142.1K
  • Earning Date
  • CCO 08-05-2025
  • ORKA 08-11-2025
  • Dividend Yield
  • CCO N/A
  • ORKA N/A
  • EPS Growth
  • CCO N/A
  • ORKA N/A
  • EPS
  • CCO 0.04
  • ORKA N/A
  • Revenue
  • CCO $1,538,895,000.00
  • ORKA N/A
  • Revenue This Year
  • CCO $5.23
  • ORKA N/A
  • Revenue Next Year
  • CCO $3.41
  • ORKA N/A
  • P/E Ratio
  • CCO $29.10
  • ORKA N/A
  • Revenue Growth
  • CCO 31.61
  • ORKA N/A
  • 52 Week Low
  • CCO $0.81
  • ORKA $5.49
  • 52 Week High
  • CCO $1.77
  • ORKA $52.32
  • Technical
  • Relative Strength Index (RSI)
  • CCO 62.18
  • ORKA 59.14
  • Support Level
  • CCO $1.02
  • ORKA $14.10
  • Resistance Level
  • CCO $1.22
  • ORKA $15.76
  • Average True Range (ATR)
  • CCO 0.07
  • ORKA 1.12
  • MACD
  • CCO 0.02
  • ORKA 0.04
  • Stochastic Oscillator
  • CCO 98.08
  • ORKA 83.71

About CCO Clear Channel Outdoor Holdings Inc.

Clear Channel Outdoor Holdings Inc is a provider of out-of-home advertising solutions. The company offers advertisers an opportunity to reach mass audiences across various high-traffic public spaces, by using its diverse portfolio of assets including roadside billboards, street furniture, and airport displays. Its reportable segments are; America (U.S. operations excluding airports), Airports (U.S. and Caribbean airport operations), and Other. A majority of its revenue is generated from the America segment which generates revenue from the sale of advertising on printed and digital out-of-home advertising displays such as bulletins, posters, street furniture, and others. Geographically, the company generates maximum revenue from the United States followed by Singapore.

About ORKA Oruka Therapeutics Inc. Common Stock

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Share on Social Networks: